These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11460042)

  • 1. [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases].
    Richard MA; Fiszenson F; Jreissati M; Jean Pastor MJ; Grob JJ
    Ann Dermatol Venereol; 2001; 128(6-7):759-61. PubMed ID: 11460042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity to paroxetine.
    Mera MT; Pérez BV; Fernández RO; Iglesias JF
    Allergol Immunopathol (Madr); 2006; 34(3):125-6. PubMed ID: 16858890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photosensitivity associated with selective serotonin reuptake inhibitors.
    Doffoel-Hantz V; Boulitrop-Morvan C; Sparsa A; Bonnetblanc JM; Dalac S; Bédane C
    Clin Exp Dermatol; 2009 Dec; 34(8):e763-5. PubMed ID: 19817765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary dermatologic effects of serotonin reuptake inhibitor antidepressants: hypothesis of cross-reacting allergy. Apropos of 2 cases].
    Beauquier B; Fahs H
    Encephale; 1998; 24(1):62-4. PubMed ID: 9559306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angular cheilitis after paroxetine treatment.
    Verma R; Balhara YP; Deshpande SN
    J Clin Psychopharmacol; 2012 Feb; 32(1):150-1. PubMed ID: 22217958
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
    Mandrioli R; Mercolini L; Saracino MA; Raggi MA
    Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urticarial vasculitis secondary to paroxetine.
    Welsh JP; Cusack CA; Ko C
    J Drugs Dermatol; 2006; 5(10):1012-4. PubMed ID: 17373154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Citalopram-induced subacute cutaneous lupus erythematosus -- first case and review concerning photosensitivity in selective serotonin reuptake inhibitors.
    Röhrs S; Geiser F; Conrad R
    Gen Hosp Psychiatry; 2012; 34(5):541-5. PubMed ID: 22534401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
    Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E
    Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
    Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
    Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
    Hieronymus F; Lisinski A; Nilsson S; Eriksson E
    Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D
    Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The serotonin syndrome].
    Kozian R
    Psychiatr Prax; 2005 Oct; 32(7):367-9. PubMed ID: 16220422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-sensitivity between paroxetine and sertraline.
    Warnock CA; Azadian AG
    Ann Pharmacother; 2002 Apr; 36(4):631-3. PubMed ID: 11918512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.